ENGENE HOLDINGS INC.
ENGN evidence brief
What we can confirm
- BioSniper Score:
- 6.7 / 10
- Market Cap:
- $118.6M
- Lead Asset:
- detalimogene (Phase 2)
What it means
What to watch
Prepared research question
What matters most for ENGN—catalysts, financial risk and supporting evidence?
Traceable citations · Unknowns marked
BioSniper AI · ENGN
enGene Holdings Inc. is a clinical-stage biotechnology company developing detalimogene, a non-viral gene therapy for bladder cancer, with no approved products or revenue and a recent strategic restructuring to preserve cash.
Key risk: No revenue, ongoing losses
BioSniper Score
Based on 3 of 6 signals
Limited data coverage
Market Cap
$118.6M
Cash Runway
—
Lead Asset
detalimogene (Phase 2)
Next Catalyst
—
Financial data as of Jul 31, 2026.
Tracking 2 pipeline candidates for ENGENE HOLDINGS INC..
enGene Holdings Inc. is a clinical-stage biotechnology company developing detalimogene, a non-viral gene therapy for bladder cancer, with no approved products or revenue and a recent strategic restructuring to preserve cash.
- enGene has no approved products and has not generated any revenue from product sales [sec_mda · as of 2026-09-08].
- Net loss was $32.5 million for the three months ended July 31, 2026, and $92.5 million for the nine months ended July 31, 2026 [sec_mda · as of 2026-09-08].
- Cash & equivalents were $41.0M as of 2026-07-31 [sec].
- In June 2026, the company reduced its workforce by approximately 50% to streamline operations and preserve cash [sec_mda · as of 2026-09-08].
- The company stopped enrollment in additional cohorts of the LEGEND trial and plans to discuss strategy with the FDA in Q4 2026 [sec_mda · as of 2026-09-08].
What works
- detalimogene demonstrated an any-time complete response rate of 54.0% among evaluable patients in the pivotal cohort of the LEGEND trial as of April 21, 2026 [sec_mda · as of 2026-09-08].
- The company expects to engage with the FDA and initiate a BLA submission in the fourth quarter of calendar year 2026 [sec_mda · as of 2026-09-08].
- Shareholders' equity stood at $230.3M as of 2026-07-31, providing a capital base [sec].
What to weigh
- enGene has never been profitable and has incurred net losses since inception [sec_mda · as of 2026-09-08].
- The company has no approved products and no revenue from product sales [sec_mda · as of 2026-09-08].
- Cash conservation efforts include a 50% workforce reduction and halting enrollment in additional LEGEND trial cohorts [sec_mda · as of 2026-09-08].
- The company needs substantial additional funding to support continuing operations and growth strategy [sec_mda · as of 2026-09-08].
From the filings
Quoted directly from source documents.
No approved products or revenue from product sales
“We do not have any products approved for sale and have not generated any revenue from product sales.”
SEC MD&A · September 8, 2026
Net loss for three months ended July 31, 2026
“Our net loss was $32.5 million and $92.5 million for the three and nine months ended July 31, 2026”
SEC MD&A · September 8, 2026
Workforce reduction of approximately 50%
“we announced the implementation of a plan to reduce our workforce by approximately 50% to streamline operations and preserve cash.”
SEC MD&A · September 8, 2026
Stopped enrollment in additional LEGEND trial cohorts
“the Company has stopped enrollment in all additional cohorts of the LEGEND trial and plans to reevaluate its strategy for these cohorts following discussion with the FDA in the fourth quarter of calendar year 2026.”
SEC MD&A · September 8, 2026
Risks & what to watch (4)›
Key risks
- No revenue, ongoing losses — Company has never been profitable and has no product revenue; net loss of $92.5M in nine months ended July 31, 2026 [sec_mda · as of 2026-09-08].
- Cash runway uncertainty — Cash & equivalents $41.0M as of 2026-07-31; company needs substantial additional funding [sec_mda · as of 2026-09-08].
- Clinical trial disruption — Enrollment stopped in additional LEGEND trial cohorts; strategy reevaluation pending FDA discussion [sec_mda · as of 2026-09-08].
- Workforce reduction impact — 50% workforce reduction may affect operational capacity and timelines [sec_mda · as of 2026-09-08].
What to watch
- FDA discussion in Q4 2026 regarding LEGEND trial strategy and BLA submission path [sec_mda · as of 2026-09-08].
- Initiation of BLA submission expected in Q4 2026 [sec_mda · as of 2026-09-08].
- Updated data on key regulatory endpoints for the pivotal cohort of the LEGEND trial in Q4 2026 [sec_mda · as of 2026-09-08].
- Cash burn rate and any new financing activities given $41.0M cash position [sec].
Sources: SEC filings · SEC MD&A · Generated October 13, 2026 · How we verify sources →
Run ENGENE HOLDINGS INC. through your own thesis
Use the pipeline, catalyst, financial, FDA, and market facts on this page as inputs to a protocol you control.
Your protocol can:
- Turn available ENGENE HOLDINGS INC. facts into screen rules or deeper checks
- Show cited findings, blockers, and unresolved evidence together
- Save the logic and rerun it as the company evidence changes
Evidence & data
Score breakdownBased on 3 of 6 signals · derived from public data
Cash runway data unavailable
D/E 0.25 · 0% dilution
Lead: Phase 2
2 candidates
No upcoming catalysts tracked
No insider transactions in the last 180 days
Pipeline
Financials
Short Interest
as of Apr 20, 2026- % of float
- 2.2%
- Days to cover
- 2.0
- Shares short
- 1,145,907
- Daily short volume
- -
Short percent of float and days-to-cover reflect reported short positioning. Daily short volume is the exchange-reported short share of a single day's trading volume and is noisier. See the most-shorted biotech ranking →
ENGN short interestGovernance
Frequently asked questions
What is the AI investment thesis for ENGENE HOLDINGS INC.?
enGene Holdings Inc. is a clinical-stage biotechnology company developing detalimogene, a non-viral gene therapy for bladder cancer, with no approved products or revenue and a recent strategic restructuring to preserve cash.
What is ENGENE HOLDINGS INC.'s lead drug candidate?
ENGENE HOLDINGS INC.'s most advanced tracked candidate is detalimogene (Phase 2) for high-risk BCG-unresponsive NMIBC with CIS.
Who is the CEO of ENGENE HOLDINGS INC.?
Mr. Ronald H. W. Cooper is the chief executive officer of ENGENE HOLDINGS INC. (ENGN).
Where is ENGENE HOLDINGS INC. headquartered?
ENGENE HOLDINGS INC. (ENGN) is headquartered in Montreal, QC, Canada.
What therapeutic areas does ENGENE HOLDINGS INC. focus on?
ENGENE HOLDINGS INC. develops therapies across Rare Disease, Respiratory.
The AI overview and BioSniper Score are neutral, data-derived signals built from public SEC filings, ClinicalTrials.gov and FDA records — not investment advice.